In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Best of the Blog: IN VIVO, April 2009

Executive Summary

A selection of our favorite blog posts from April 2009 for stories not covered elsewhere in this month's IN VIVO. (See them for free at http://invivoblog.blogspot.com/).

You may also be interested in...



Troubled Biotechs (UK Edition): Summit, Alizyme, ReNeuron

More than a third of UK biotechs are short of cash, and those that haven’t already found creative means of monetizing their assets have run out of time.

BMS's Rebloyzl Data Supports Adding Less Severe Patients To Label

Adding non-transfusion-dependent anemia patients to the Reblozyl label is a key strategy for the product, which BMS expects to reach $4bn in annual sales.

Doctors Frustrated By Lack Of Guidance On Who Should Get Aduhelm

Biogen has warned that uptake for its newly approved Alzheimer’s therapy will be slow in the beginning and doctors confirm it will take time to figure which patients can and should be treated.

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV003298

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel